Physician profile
Charles Bradley Franz
NPI 1215973995
$728,011.67
in general payments reported to CMS, 2019-2025
28 companies · $175K in 2025
The $175K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $45K · 2021: $42K · 2022: $129K · 2023: $110K · 2024: $167K · 2025: $175K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $399K · Travel and Lodging: $37K · Food and Beverage: $14K · Consulting Fee: $2,000 · Education: $13.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $399,103.75 |
| Travel and Lodging | $36,519.66 |
| Food and Beverage | $14,246.32 |
| Consulting Fee | $2,000.00 |
| Education | $13.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $220,853.77 | 2019-2025 | |
| Janssen Biotech, INC. | $201,656.90 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Janssen Scientific Affairs, LLC | $141,992.15 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $96,168.16 | 2019-2025 | Dupixent |
| Genzyme Corporation | $62,805.71 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $702.62 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $626.65 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $430.52 | 2019-2025 | |
| Galderma Laboratories, L.P. | $386.65 | 2019-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $378.20 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $315.14 | 2019-2025 | |
| Dermavant Sciences, INC. | $297.35 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $248.86 | 2019-2024 | Jublia, Targretin, Arazlo |
| Ucb, INC. | $223.52 | 2019-2025 | Bimzelx, Cimzia |
| Prugen, INC. Pharmaceuticals | $184.38 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $137.16 | 2023-2025 | Zoryve |
| Incyte Corporation | $93.50 | 2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $92.37 | 2019-2024 | Ilumya |
| Sanofi-Aventis U.S. LLC | $86.19 | 2021 | |
| Dermira, INC. | $71.91 | 2019-2020 | |
| Amgen INC. | $57.38 | 2019 | |
| Genentech USA, INC. | $48.14 | 2019 | |
| Organon LLC | $39.65 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.57 | 2022-2024 | Spevigo |
| Vyne Pharmaceuticals INC. | $32.39 | 2020 | |
| Ironwood Pharmaceuticals, INC | $18.98 | 2022 | |
| Organogenesis INC. | $15.04 | 2025 | Via Matrix |
| Verrica Pharmaceuticals INC. | $13.81 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Franz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.